Confronto
Icatibant vs. Leuprorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
138614-30-9
53714-56-0
Peso molecolare
1304.52 g/mol
1209.4 g/mol
Emivita
nessun dato
3 h
Sequenza
nessun dato
Pyr-His-Trp-Ser-Tyr-D-Leu-Leu-Arg-Pro-NHEtMeccanismo d'azione
Icatibant
Icatibant competitively blocks the bradykinin B2 receptor. Because bradykinin mediates the vascular permeability, swelling and pain typical of hereditary angioedema, the blockade interrupts the acute attack.
Leuprorelin
Leuprorelin is a GnRH-receptor agonist. After binding to pituitary GnRH receptors, it first causes a transient surge in luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release — the so-called flare. With continuous, non-pulsatile exposure the receptors are downregulated and desensitized, suppressing gonadotropin secretion and consequently lowering sex steroids (testosterone or estradiol) to low levels. This mechanism underlies the literature-described use in hormone-dependent conditions.
Base di evidenze
Evidenza più alta
RCT sull'uomo
RCT sull'uomo
Studi
1
4
di cui sull'uomo
1
4
Effetti registrati
1
4
Contraddizioni aperte
0
1
Eventi avversi documentati
1
3
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Icatibant and Leuprorelin?
- Icatibant is classified as "Ricerca (altro)", while Leuprorelin is classified as "Ricerca (altro)". Icatibant: Icatibant is a synthetic decapeptide and selective antagonist of the bradykinin B2 receptor. It is approved to treat acute attacks of hereditary angioedema (HAE). Leuprorelin: Leuprorelin (also leuprolide) is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH/LHRH). It is an approved prescription medicine in several jurisdictions, including for advanced prostate cancer, endometriosis, uterine fibroids and central precocious puberty. This page neutrally summarizes the evidence base and legal status and is not a usage or dosing recommendation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Icatibant or Leuprorelin?
- The highest available evidence level is "RCT sull'uomo" for Icatibant and "RCT sull'uomo" for Leuprorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Icatibant and Leuprorelin in Germany and the United States?
- Germania: Icatibant — Su prescrizione, Leuprorelin — Su prescrizione. Stati Uniti: Icatibant — Su prescrizione, Leuprorelin — Su prescrizione. These are factual summaries with source and review date on the individual pages.